Charles River Laboratories International, Inc. (CRL) vs Medpace Holdings, Inc. (MEDP)

A side-by-side comparison of Charles River Laboratories International, Inc. and Medpace Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total returnCRL vs MEDP

growth of $100 · dividends reinvested · last 10y
CRL +199.6%MEDP +2015.0%MEDP compounded faster
Log scale — wide-divergence pair
101001k10kStart $10020182020202220242026$300$2,115
CRL MEDP

CRL vs MEDP: by the numbers

  • MEDP is the larger company ($16.41B vs $12.56B market cap).
  • MEDP is profitable (17.67% net margin) while CRL runs a net loss (-5.96%).
  • MEDP grew revenue faster over the past five years (22.03% vs 4.08% CAGR).

Metrics side by side

Valuation

MetricCRLMEDP
P/E ratioN/A34.43
Forward P/E23.4833.39
P/S ratio3.166.08
P/B ratio4.4538.96
PEG ratioN/A1.82
EV / EBITDA19.5527.03
FCF yield2.93%4.34%

Profitability

MetricCRLMEDP
Gross margin32.24%28.76%
Operating margin12.35%20.97%
Net margin-5.96%17.67%
ROE-8.40%113.29%
ROIC8.36%67.94%

Growth (annualized)

MetricCRLMEDP
Revenue CAGR (5Y)4.08%22.03%
EPS CAGR (5Y)-47.86%30.90%
FCF CAGR (5Y)6.43%23.40%
Total return CAGR (5Y)-8.66%26.69%

Frequently asked

Which has grown faster, CRL or MEDP?
Over the past five years, MEDP grew revenue faster — CRL at a 4.08% CAGR versus MEDP at 22.03%.
Is CRL or MEDP more profitable?
MEDP runs the higher net margin — CRL at -5.96% versus MEDP at 17.67%.
How have CRL and MEDP total returns compared?
Over the past 5 years, CRL delivered 11.77% and MEDP delivered 26.69% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 6, 2026.